China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by China’s volume-based procurement (VBP) program....

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor...

Sanofi to acquire Origimm Biotechnology in a bid to expand vaccine pipeline

Sanofi will acquire Origimm Biotechnology as per an agreement signed by the two healthcare companies. The deal is expected to be finalized...

Is Biogen’s Alzheimer’s drug worth $56K? Experts say $8400 and raise questions about efficacy

Aduhelm, Biogen’s new drug for Alzheimer’s disease, which was approved by FDA contentiously last month, continues to face criticism since then.

AstraZeneca and FibroGen hit FDA committee’s safety data firewall for roxadustat

Two roxadustat partners AstraZeneca and FibroGen have received objections regarding safety concerns of their drug from the FDA after which the two companies

NRx Pharmaceuticals signs deal for clinical trials of Israel’s homegrown Covid-19 vaccine

Israel Institute for Biological Research (IIBR), an institute run by Israel’s Defense Ministry, has signed a memorandum of understanding (MoU) with the NRx Pharmaceuticals

Pharma manufacturers lawsuits against payers and benefit managers preferred drugs are on FTC’s radar

The attention of federal antitrust regulators has been drawn to a slew of lawsuits filed by pharmaceutical companies, challenging the “preferred” medicine list of payers and benefit managers.

Roche to lay off 300 to 400 employees in product development jobs

Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Aridis receives FDA agreement on single Phase 3 study for AR-301

Aridis Pharmaceuticals, Inc. received encouraging FDA feedback...

First patient dosed with Biogen’s litifilimab in CLE study

Global litifilimab phase 2/3 study has seen...

Defender Pharmaceuticals Confronts FDA Setback in Approval Journey for Nasal Motion Sickness Gel

Defender Pharmaceuticals, headquartered in St. Louis, faces...